Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), a medical technology company focused on saving lives by making an ECG a far more valuable screening tool through the use of artificial intelligence, today announced it has been granted Korean Patent No. 10-2490960 from the Korean Intellectual Property Office.
To date HeartSciences has been granted nine US patents and 30 international patents for a total of 39 granted patents, with nine additional patents pending across the US and international markets.
"Given the scale of the global market, protection of our intellectual property and patents in major markets is core to the Company as it provides intrinsic value to HeartSciences and would be expected to be a source of major competitive advantage as we move toward commercialization. This latest patent further expands our international coverage and is the latest addition to our extensive patent portfolio," said Andrew Simpson, CEO of HeartSciences.
Investor contact
Mark Komonoski, Integrous Communications · 877-255-8483 · [email protected]